General Info
Omri Amirav Drory is a General Partner at NFX Bio. His investment thesis revolves around the intersection of biology and technology. Omri focuses on pre-seed and seed stage startups, with investments typically ranging between $1.5M to $3M. He has made significant investments in the field of biology and techbio. Omri’s check sizes usually fall between $500K to $5.0M per company. He actively collaborates with companies like AstraZeneca, Karkinos Healthcare, and OncoDNA, showing a preference for strategic partnerships and collaborations in the industry.
Location:
Country: Israel
Industries:
Investment Regions: EU, LATAM
Investment Stages: pre-seed, seed
angel-individual
EU, LATAM
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: very-active
AI Reasoning: Signal NFX shows a Series A investment in Centivax in July 2025 and multiple seed investments in 2024 (TwoStep Therapeutics – Jun 2024, Radar Therapeutics – May 2024). The most recent known investment is Centivax Series A in July 2025, which is less than 6 months before the reference date, so classify as very-active. Example startups invested: Centivax, TwoStep Therapeutics, Radar Therapeutics.
Angel activity thresholds:
Low Activity – Only known angel investments more than 12 months ago.
Active – Known angel investments between the last 12 and 6 months.
Very Active – Known angel investments in the last 6 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
…
…
…
…
…
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of Omri Amirav Drory
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI